News & Research
New studies, trials, regulatory changes and news about the compounds on Amino WRX. Items are collected automatically once a day and summarised by AI; they are not reviewed by an editor before they appear here. Read the original source before relying on anything.
Last updated 2026-10-16.
- RegulatorySLU-PP-332 (injectable)SLU-PP-332 (oral)SLU-PP-332 + 5-Amino-1MQ blend (oral)SLU-PP-332 + BAM-15 blend (oral)SLU-PP-332 + Orforglipron blend (oral)SLU-PP-9152026-10-162027 WADA Prohibited List: What Changes?
Fox Mandal
The 2027 WADA Prohibited List, effective 1 January 2027, names peptides as examples of non-approved substances and adds SLU-PP-332 and SLU-PP-915 as prohibited metabolic modulators. People covered by these anti-doping rules would not be allowed to use SLU-PP-332 after that date, while GLP-1 agonists such as semaglutide and tirzepatide remain permitted but monitored.
- Trump administration advances plan for peptide drugs favored by RFK Jr.
STAT News
Health officials have sent the White House a draft interim policy that would let pharmacies temporarily compound certain unapproved peptides, including BPC-157. The proposal is not an FDA approval, so compounded BPC-157 would remain unapproved while the review is pending.
- TG SAFE warns against unapproved weight-loss drugs and peptides
Hyderabad Mail
Telangana’s drug authority warned against buying unapproved weight-loss drugs and experimental peptides, including orforglipron, tesamorelin, BPC-157, GHK-Cu and retatrutide, from unregulated online sellers. It said research-use labels do not make these products approved medicines and cited contamination, infection and other risks from injectables.
- US FDA Peptide Compounding Policy: What Could Change?
Medindia
The public regulatory record shows an interim peptide-access filing was received on 14 October 2026 and is still pending, and it does not name covered peptides or lift existing limits. FDA has also said published safety information on compounded BPC-157 is too limited to judge its harms.
- Regulatory2026-10-15Peptides Interim Access Policy Advancing Despite US FDA Staff Concerns
Pink Sheet
White House reviewers are considering a temporary order that would allow compounding and dispensing of certain unapproved injectable peptides, despite concerns from career FDA staff. If issued, the order would be a short-term access step and not a finding that those peptides are safe or approved.
- Thymosin-α1 for Recurrent Implantation Failure
ClinicalTrials.gov
A clinical trial of thymosin alpha-1 for recurrent implantation failure is recruiting. It is early human research in a fertility setting and has not reported results.
- SYNCHRONIZE-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
ClinicalTrials.gov
A not-yet-recruiting trial, SYNCHRONIZE-HERA, will test survodutide for weight loss in women with overweight or obesity who are in menopause or have finished it. No results are available because enrollment has not started.
- New compoundVK27352026-10-14Viking Starts Phase 3 SUNRISE Program for Oral VK2735 in Obesity
BioPharm International
Viking Therapeutics has started Phase 3 SUNRISE trials of oral VK2735, a dual GLP-1/GIP agonist, for obesity. Each of two 68-week studies, one with type 2 diabetes and one without, plans to enroll 560 adults, and this report does not include efficacy results.
- Peptides: FDA urged to overrule advisory panel
Center for Science in the Public Interest
The Center for Science in the Public Interest asked the FDA to reject a pharmacy compounding advisory vote that recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for the 503A bulks list. The group says the vote set aside FDA staff safety objections, and the request itself does not change current compounding rules.
- A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
ClinicalTrials.gov
A recruiting trial is testing whether survodutide helps people with type 2 diabetes control blood sugar. Results have not been posted.
- CagriSema: Results, Side Effects, and FDA Approval
Healthline
CagriSema, a combination of cagrilintide and semaglutide, remains unapproved, with an FDA decision expected in late 2026. The FDA has also said cagrilintide cannot legally be used in compounding.
- Regulatory2026-10-08US FDA Staff Push Back Against Trump Administration Interim Peptide Dispensing Order
Pink Sheet
FDA drug-center staff are reported to be unwilling to recommend a temporary order letting compounding pharmacies dispense certain unapproved peptides while permanent rules are drafted. They cited safety and the formal approval process, so compounded research peptides are not described as newly authorized.
- Retatrutide and Survodutide Make Inroads Into Weight Loss for Diabetic Patients
TCTMD
In adults with obesity and type 2 diabetes, once-weekly survodutide cut weight by 13.1% at 6.0 mg and 10.4% at 3.6 mg after 76 weeks, versus 3.1% on placebo, in SYNCHRONIZE-2 published in NEJM. The same report says retatrutide cut weight by about 19% at the 9 mg and 12 mg doses after 80 weeks, versus about 4% on placebo, in TRIUMPH-2 published in The Lancet.
- New compoundretatrutide2026-10-13Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame?
CBS News
Two unverified FDA adverse-event reports name unapproved retatrutide from unofficial sources in connection with deaths, and causation has not been established. Poison centers also logged 862 retatrutide exposures in the three months ending September.
- Regulatory2026-10-08The Trump administration seems like its leaning toward allowing unapproved peptides
The Verge
The administration is reported to be considering temporary sales of some unapproved peptides through compounding pharmacies. Which peptides would be covered, and when any order would start, has not been decided.
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) (recruiting)
ClinicalTrials.gov
ATTAIN-Outcomes is a recruiting trial of oral orforglipron on cardiovascular outcomes in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease. Heart and kidney outcome data for orforglipron are not yet available from this record.
- Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency (recruiting)
ClinicalTrials.gov
A phase 3 trial of LUM-201, the oral growth hormone secretagogue also known as ibutamoren (MK-677), is recruiting children with growth hormone deficiency. It is a large human efficacy and safety study of this compound, in children rather than adults.
- Regulatory2026-10-12WADA publishes Prohibited List update for 2027
World Triathlon
The 2027 WADA Prohibited List, in force from 1 January 2027, adds examples under S0 non-approved substances. GLP-1 agonists, including semaglutide and tirzepatide, are left not prohibited while more data are collected.
- A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity (recruiting)
ClinicalTrials.gov
A recruiting trial is testing orforglipron in people with overweight who are at risk of obesity-related complications or of progressing to class 1 obesity. It looks at earlier use, before established obesity, and has not reported results.
- Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (recruiting)
ClinicalTrials.gov
A recruiting trial is evaluating the efficacy and safety of orforglipron in people with peripheral artery disease. It moves human testing of this oral GLP-1 receptor agonist into a vascular-disease population, without results yet.
- Thymalfasin for Immune Recovery in Adults With Sepsis (recruiting)
ClinicalTrials.gov
A recruiting trial is studying thymalfasin, another name for thymosin alpha-1, for immune recovery in adults with sepsis. It is new human research on this peptide in critical illness, with no results reported yet.
- Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity (recruiting)
ClinicalTrials.gov
A recruiting trial is testing whether mazdutide changes coronary plaque in people with coronary atherosclerosis and overweight or obesity. It extends human study of mazdutide to a cardiovascular imaging outcome, but results are not yet available.
- New compoundpetrelintide2026-10-13Bootleg Retatrutide Deaths? PMOS and Dementia; Weight-Loss Drug to Be Discontinued
MedPage Today
A phase 2 trial of Zealand’s amylin analog petrelintide found up to 9.2% weight loss at 28 weeks, compared with 2% on placebo, in people with overweight or obesity and type 2 diabetes. That is early human evidence for another amylin-pathway peptide being studied for weight loss.
- Trialretatrutide2026-10-08The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) (active not recruiting)
ClinicalTrials.gov
TRIUMPH-Outcomes is testing once-weekly retatrutide for cardiovascular and kidney outcomes in adults living with obesity. The trial is active and no longer recruiting, and this registry update does not report results.
- New compoundretatrutide2026-10-12The Lancet
The Lancet
The Lancet pointed to TRIUMPH-2, in which retatrutide reduced body weight and improved glycemic and cardiometabolic measures in people with obesity and type 2 diabetes. Journal publication is a major human-results milestone for this unapproved triple agonist.
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee (active not recruiting)
ClinicalTrials.gov
A trial of orforglipron in people with obesity or overweight and knee osteoarthritis is active and no longer recruiting. It is testing the drug in a joint-disease population, and this update does not include results.
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting (recruiting)
ClinicalTrials.gov
A recruiting trial is studying orforglipron in people with type 2 diabetes who observe Ramadan fasting. It should clarify use during prolonged daily fasting, which standard obesity trials do not address, and results are not in yet.
- A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems (not yet recruiting)
ClinicalTrials.gov
A trial of orforglipron in Chinese participants with obesity or overweight and weight-related health problems is registered but not yet recruiting. It is meant to produce population-specific human data that are still missing.
- A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (recruiting)
ClinicalTrials.gov
A recruiting trial is testing orforglipron in women who have stress urinary incontinence and obesity or overweight. It asks whether treatment in this group affects a symptom that often tracks with weight, and results are pending.
- WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight
Reuters
New WHO child-obesity guidance advises against weight-loss drugs under age 10 and allows them at ages 10 to 19 only after supervised lifestyle care has failed. It cites limited GLP-1 evidence on safety and long-term effectiveness, while noting Wegovy and Saxenda are already approved for some adolescents.
- Zurich doctors report a woman hospitalized after a life coach injected an unverified retatrutide product
Peptide News Digest
Doctors in Zurich reported that a woman was hospitalized with days of vomiting after a life coach gave her four rising doses of an unapproved product said to contain retatrutide. The case is a safety signal about unverified research-chemical injections, not a controlled result for pharmaceutical retatrutide.
- New compoundPetrelintide2026-10-07Zealand, Roche’s obesity drug helps patients lose up to 9.2% weight in mid-stage trial
Reuters
Once-weekly petrelintide, an amylin-analog peptide, produced 7.4 to 9.2 percent weight loss at 28 weeks, compared with about 2 percent for placebo, in 220 adults with overweight or obesity and type 2 diabetes. Gastrointestinal dropouts were similar to placebo, and a Phase 3 program in about 7,000 people is already underway.
- WHO guidelines on the integrated management of obesity in children
World Health Organization
WHO’s guideline on obesity in children under 10 recommends against medicines, including GLP-1 drugs, because safety and long-term effectiveness are not established. It puts structured lifestyle care first and treats drug treatment as unproven in that age group.
- News2026-10-07Trump administration paving way for temporary sale of some unapproved peptides
The Washington Post
Officials are discussing temporary enforcement discretion that could let compounding pharmacies dispense some previously restricted, unapproved peptides before formal rulemaking. No policy has been announced, timing is unclear, and the peptides have not been named.
- Semaglutide and Tirzepatide Suppress Hepatic Fatty Acid Uptake and Fatty Acid β-Oxidation in High-Fat Diet-Induced Obesity Mice
J Proteome Res
In mice with diet-induced obesity, semaglutide and tirzepatide reduced hepatic fatty acid uptake and fatty acid oxidation. The paper is laboratory evidence about liver fat handling, not a human trial of liver benefit.
- New compoundPetrelintide2026-10-07ZUPREME-2: Petrelintide outperforms placebo for weight loss in T2D and obesity
HCPLive
A report on the ZUPREME-2 trial says petrelintide also lowered HbA1c by 0.61 to 0.88 points more than placebo in adults with type 2 diabetes and obesity. No unexpected safety signals were described alongside the weight-loss result.
- Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD (recruiting)
ClinicalTrials.gov
A recruiting study is measuring visceral fat and liver changes in people with chronic kidney disease who receive semaglutide. No outcomes are available yet, so this is a trial start rather than new evidence of benefit or harm.
- Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide (active not recruiting)
ClinicalTrials.gov
A ClinicalTrials.gov record lists a cagrilintide weight-loss study in adults with overweight or obesity and type 2 diabetes as active but not recruiting. No results are posted, so the record shows the trial is underway rather than what weight change it produced.
- Russian Football Union medical department: What will change in the WADA Prohibited List in 2027
Russian Football Union
A Russian Football Union medical briefing on the 2027 WADA Prohibited List says that from 1 January 2027 BPC-157 will be named as an S0 example and SLU-PP-332 and SLU-PP-915 will be named as metabolic-modulator examples. The briefing also says unapproved peptides that are not listed by name can still be prohibited under S0, S2, or S4.
- Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
Pharmacy Times
Phase 3 ACHIEVE-4, published in The Lancet, found once-daily orforglipron was noninferior to insulin glargine for major cardiovascular events in 2,749 high-risk adults with type 2 diabetes. People taking orforglipron lost more weight, reduced A1C more, and had less hypoglycemia, but had more gastrointestinal side effects.
- New compoundPetrelintide2026-10-06Petrelintide Yields Up to 10.7% Weight Loss With Mild GI Effects
Pharmacy Times
A phase 2 trial published in The Lancet Diabetes & Endocrinology found that petrelintide, a long-acting amylin analog, produced up to 10.7% weight loss at 42 weeks. Nausea was mostly mild and occurred mainly during dose escalation.
- A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus (active not recruiting)
ClinicalTrials.gov
An ongoing trial is measuring how retatrutide affects insulin secretion and insulin sensitivity in adults with type 2 diabetes. No results have been released, so its effect on insulin function is not yet known.
- Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes (active not recruiting)
ClinicalTrials.gov
An active trial is comparing once-weekly ribupatide with semaglutide and placebo in people with obesity who do not have diabetes. Efficacy and safety results have not been released.
- Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction.
Eur Heart J
In an animal model of heart failure with preserved ejection fraction, semaglutide reduced cardiac and hepatic remodelling even when the effect was separated from weight loss. This is laboratory evidence only and does not show that the same benefit occurs in people.
- Semaglutide Normalized Liver Fat in Most Adults With Obesity
Pharmacy Times
A post hoc MRI subgroup from STEP UP, presented at EASD 2026, found that pooled semaglutide 7.2 mg and 2.4 mg lowered mean liver fat from 8.8% to 3.1% at 72 weeks in adults with obesity. No placebo comparison was reported for that endpoint, so the drug-specific effect is uncertain.
- GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes (recruiting)
ClinicalTrials.gov
A recruiting study is examining GLP-1 receptor agonist use and sarcopenia in people with obesity who do not have diabetes. It has not reported results, so this listing does not establish a link with muscle loss.
- The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial (active not recruiting)
ClinicalTrials.gov
A placebo-controlled trial is testing how oral semaglutide affects bone turnover in people with type 2 diabetes. Results are not yet available, so effects on bone remain unknown.
- The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity (recruiting)
ClinicalTrials.gov
A recruiting trial is testing tirzepatide for menopausal hot flashes and markers of biological aging in postmenopausal women with obesity. No results are available, so any benefit for those symptoms is unproven.
- Orforglipron Shows Greater A1C, Weight Reduction Than Oral Semaglutide
Drug Topics
An indirect comparison estimated that orforglipron 17.2 mg reduced weight by about 1.5 percentage points and A1C by about 0.3 percentage points more than oral semaglutide 25 mg at 52 weeks. It was not a head-to-head trial, so the difference is less certain than a direct comparison.
- Post-Initiation Care Patterns and Weight Loss With Semaglutide and Tirzepatide for Obesity in Clinical Practice
medRxiv
A preprint described care patterns and weight loss after people started semaglutide or tirzepatide for obesity in ordinary clinical practice. The estimates are preliminary because the report has not been peer reviewed.
- The Week Progress Got More Specific
Vastkind
A briefing on the TRIUMPH-2 diabetes trial of retatrutide (GLP3-R) separates an 18.8% treatment-regimen weight-loss figure from a 20.8% efficacy estimate. It also notes a planned United States filing in early 2027, which is a regulatory step and not an approval.
- Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
Rapid Communications in Mass Spectrometry
A mass-spectrometry study reports how retatrutide, the compound this site lists as GLP3-R, can be detected in human plasma and urine and describes its excretion profile. The findings matter for sports-drug testing because they show the compound can be identified in biological samples.
- Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity
Pharmacy Times
Phase 3 TRIUMPH-2, published in The Lancet, found retatrutide, sold in research channels as GLP3-R, cut weight by up to 18.8% at 80 weeks in type 2 diabetes, with more hypotension and dysesthesia. Lilly is aiming at an FDA filing in early 2027, which is not an approval.
- EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.
J Hepatol
European liver, diabetes, and obesity societies issued guidance on using semaglutide as MASH-targeted therapy. The GLP1-S page should treat MASH as a human-guidance use and cite this, rather than leaving liver benefit at a lower grade.
- CagriSema Curbs 'Food Noise,' Organ Fat in Patients With Obesity, T2D Respectively
Pharmacy Times
EASD abstracts reported that cagrilintide plus semaglutide changed brain responses to high-calorie food cues and reduced liver and pancreas fat. An FDA weight-management decision is expected in the fourth quarter of 2026, so the pages should record that timeline without treating conference abstracts as a full regrade.
- New Easier-to-Use GLP-1 Pill Safe for the Heart, Study Says
MedPage Today
ACHIEVE-4 found orforglipron noninferior to insulin glargine for MACE-4, 4.2% versus 5.0%, hazard ratio 0.84, but it was not powered to prove a cardiovascular benefit. The orforglipron page should call this a heart-safety comparison, not evidence that the pill prevents cardiovascular events.
- Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial
ScienceAlert
The NEJM TRIUMPH-1 trial reported about 25% weight loss at 80 weeks on retatrutide 12 mg in obesity without diabetes, and nearly 30% in a smaller two-year extension. That non-diabetes result should be stated separately from the type 2 diabetes trial on the GLP3-R page.
- Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
N Engl J Med
The New England Journal of Medicine published a trial of once-weekly survodutide in adults with obesity and type 2 diabetes. That paper should be the lead human citation for efficacy and safety on the survodutide page.
- Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.
Lancet
Lancet published the phase 3 ACHIEVE-4 trial of cardiovascular safety for oral orforglipron versus insulin glargine in type 2 diabetes at higher cardiovascular risk. This is the primary citation for any heart-safety statement on the orforglipron page.
- Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.
Clin Obes
A systematic review pooled head-to-head studies of tirzepatide versus semaglutide for weight loss. Comparative wording on the GLP2-T and GLP1-S pages should follow this human evidence rather than cross-trial claims.
- Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.
Nat Med
Nature Medicine published a randomized placebo-controlled trial of semaglutide in type 2 diabetes with kidney disease. This is primary human evidence and should set the kidney-benefit grade on the GLP1-S page.
- EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
Pharmacy Times
The same phase 2b of eloralintide plus tirzepatide cut HbA1c by up to 2.9% in adults with obesity and type 2 diabetes. Adverse-event discontinuations were 10.8% to 27% when both drugs were escalated together, which is the tolerability figure to show if the combination is mentioned.
- LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis (recruiting)
ClinicalTrials.gov
A companion LIVERAGE trial of survodutide in MASH with cirrhosis is recruiting. The page should separate this higher-risk ongoing study from any claim of benefit in advanced liver disease.
- LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis (recruiting)
ClinicalTrials.gov
The LIVERAGE trial of survodutide in MASH with moderate or advanced fibrosis is recruiting. Readers should see this as ongoing human research, not as evidence that survodutide treats liver fibrosis.
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight (recruiting)
ClinicalTrials.gov
A trial is recruiting children and adolescents with excess body weight to test cagrilintide and CagriSema. The site should say these products are not established for minors and that this is a pharmaceutical trial, not a reason to use research material in children.
- Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues.
BMJ Open
A EudraVigilance analysis examined tirzepatide reports tied to suboptimal outcomes and drug-use problems. The GLP2-T safety section should add any disproportionate real-world signals this paper actually identifies.
- Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort.
Hum Psychopharmacol
A 12-month real-world cohort tracked renal biomarkers and lithium safety after tirzepatide was started in people with bipolar disorder already on lithium. The GLP2-T safety section should cover this interaction setting and follow the signal the paper actually found.
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
CNBC
Eloralintide, a selective amylin agonist not in the catalogue, plus tirzepatide produced up to 23.3% weight loss at 48 weeks in obesity with type 2 diabetes, and Lilly plans phase 3 by year-end. The site should flag the new peptide and should not paste the combination result onto tirzepatide monotherapy.
- Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.
Clin Obes
A systematic review and meta-analysis assessed depression burden and risk in people receiving semaglutide. The GLP1-S psychiatric safety text should be aligned to the pooled result instead of left as anecdote.
- Orforglipron Noninferior to Insulin Glargine for Cardiovascular Outcomes in T2D
Medscape
The same ACHIEVE-4 readout found better A1c and weight than insulin glargine, while gastrointestinal events drove discontinuation in 15.4% versus 5.4%. Those tolerability figures belong in the orforglipron safety section beside the cardiovascular result.
- A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) (completed)
ClinicalTrials.gov
The survodutide cardiovascular outcomes trial, SYNCHRONIZE-CVOT, is listed as completed. This registry update does not include results, so no cardiovascular benefit or harm should be claimed from the status change alone.
- Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension.
JACC Case Rep
A case report describes hemodynamic compromise linked to semaglutide-associated abdominal distension. This is a rare safety signal and should be listed as a single case, not as an expected effect.
- Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
Diabetes Care
This paper estimates tirzepatide MACE benefit in SURPASS-CVOT by imputing a placebo from REWIND, rather than reporting a new outcome trial. The site should not present that estimate as direct evidence of cardiovascular benefit.
- SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight (not yet recruiting)
ClinicalTrials.gov
SYNCHRONIZE-START, a survodutide weight-loss trial in people with overweight or obesity without diabetes, is listed as not yet recruiting. The page should not describe that non-diabetes phase 3 study as enrolled or completed.
- Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.
BMJ
BMJ reported phase 3 retatrutide results suggesting weight loss of up to 25%. Use it as a journal pointer for GLP3-R, and prefer the primary trial paper for dose, duration, and population.
- Semaglutide Demonstrates Benefits Across Frailty Levels.
JAMA
JAMA reported that semaglutide showed benefits across frailty levels. If the GLP1-S page implies benefit is limited to healthier adults, this human report should be checked before that limitation is kept.
- Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.
Contemp Clin Trials
A review covers the mechanism, clinical evidence, and open questions for survodutide in obesity. It is a check on what the page should still call uncertain, not a new trial result.
- Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.
Diabetes Obes Metab
A paper reports nephroprotective effects of survodutide in hypertension-accelerated diabetic kidney disease. Confirm whether it is human or animal before it is allowed to change the kidney grade on the survodutide page.
- Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging.
Aging Cell
A study reports that elamipretide rejuvenated oocyte quality and restored female fertility during reproductive aging. The listing does not state the model, so the SS-31 page should not add a human fertility benefit until that is confirmed.
- Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds
Pharmacy Times
A Lilly-funded cross-trial model, not a head-to-head study, linked orforglipron 17.2 mg to about 1.5% more weight loss and 0.3% more A1C reduction than oral semaglutide 25 mg. The site should not upgrade comparative claims from this indirect sponsored analysis.